Native T1 mapping in transthyretin amyloidosis
Objectives The aims of the study were to explore the ability of native myocardial T1 mapping by cardiac magnetic resonance to: 1) detect cardiac involvement in patients with transthyretin amyloidosis (ATTR amyloidosis); 2) track the cardiac amyloid burden; and 3) detect early disease. Background ATT...
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2014
|
| _version_ | 1826259343361703936 |
|---|---|
| author | Fontana, M Banypersad, S Treibel, T Maestrini, V Sado, D White, S Pica, S Castelletti, S Piechnik, S Robson, M Gilbertson, J Rowczenio, D Hutt, D Lachmann, H Wechalekar, A Whelan, C Gillmore, J Hawkins, P Moon, J |
| author_facet | Fontana, M Banypersad, S Treibel, T Maestrini, V Sado, D White, S Pica, S Castelletti, S Piechnik, S Robson, M Gilbertson, J Rowczenio, D Hutt, D Lachmann, H Wechalekar, A Whelan, C Gillmore, J Hawkins, P Moon, J |
| author_sort | Fontana, M |
| collection | OXFORD |
| description | Objectives The aims of the study were to explore the ability of native myocardial T1 mapping by cardiac magnetic resonance to: 1) detect cardiac involvement in patients with transthyretin amyloidosis (ATTR amyloidosis); 2) track the cardiac amyloid burden; and 3) detect early disease. Background ATTR amyloidosis is an underdiagnosed cause of heart failure, with no truly quantitative test. In cardiac immunoglobulin light-chain amyloidosis (AL amyloidosis), T1 has high diagnostic accuracy and tracks disease. Here, the diagnostic role of native T1 mapping in the other key type of cardiac amyloid, ATTR amyloidosis, is assessed. Methods A total of 3 groups were studied: ATTR amyloid patients (n = 85; 70 males, age 73 ± 10 years); healthy individuals with transthyretin mutations in whom standard cardiac investigations were normal (n = 8; 3 males, age 47 ± 6 years); and AL amyloid patients (n = 79; 55 males, age 62 ± 10 years). These were compared with 52 healthy volunteers and 46 patients with hypertrophic cardiomyopathy (HCM). All underwent T1 mapping (shortened modified look-locker inversion recovery); ATTR patients and mutation carriers also underwent cardiac 3,3-diphosphono-1,2- propanodicarboxylicacid (DPD) scintigraphy. Results T1 was elevated in ATTR patients compared with HCM and normal subjects (1,097 ± 43 ms vs. 1,026 ± 64 ms vs. 967 ± 34 ms, respectively; both p < 0.0001). In established cardiac ATTR amyloidosis, T1 elevation was not as high as in AL amyloidosis (AL 1,130 ± 68 ms; p = 0.01). Diagnostic performance was similar for AL and ATTR amyloid (vs. HCM: AL area under the curve 0.84 [95% confidence interval: 0.76 to 0.92]; ATTR area under the curve 0.85 [95% confidence interval: 0.77 to 0.92]; p < 0.0001). T1 tracked cardiac amyloid burden as determined semiquantitatively by DPD scintigraphy (p < 0.0001). T1 was not elevated in mutation carriers (952 ± 35 ms) but was in isolated DPD grade 1 (n = 9, 1,037 ± 60 ms; p = 0.001). Conclusions Native myocardial T1 mapping detects cardiac ATTR amyloid with similar diagnostic performance and disease tracking to AL amyloid, but with lower maximal T1 elevation, and appears to be an early disease marker. |
| first_indexed | 2024-03-06T18:48:21Z |
| format | Journal article |
| id | oxford-uuid:0f529591-9559-4d1f-9b91-ef5598902f1d |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T18:48:21Z |
| publishDate | 2014 |
| record_format | dspace |
| spelling | oxford-uuid:0f529591-9559-4d1f-9b91-ef5598902f1d2022-03-26T09:50:39ZNative T1 mapping in transthyretin amyloidosisJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:0f529591-9559-4d1f-9b91-ef5598902f1dEnglishSymplectic Elements at Oxford2014Fontana, MBanypersad, STreibel, TMaestrini, VSado, DWhite, SPica, SCastelletti, SPiechnik, SRobson, MGilbertson, JRowczenio, DHutt, DLachmann, HWechalekar, AWhelan, CGillmore, JHawkins, PMoon, JObjectives The aims of the study were to explore the ability of native myocardial T1 mapping by cardiac magnetic resonance to: 1) detect cardiac involvement in patients with transthyretin amyloidosis (ATTR amyloidosis); 2) track the cardiac amyloid burden; and 3) detect early disease. Background ATTR amyloidosis is an underdiagnosed cause of heart failure, with no truly quantitative test. In cardiac immunoglobulin light-chain amyloidosis (AL amyloidosis), T1 has high diagnostic accuracy and tracks disease. Here, the diagnostic role of native T1 mapping in the other key type of cardiac amyloid, ATTR amyloidosis, is assessed. Methods A total of 3 groups were studied: ATTR amyloid patients (n = 85; 70 males, age 73 ± 10 years); healthy individuals with transthyretin mutations in whom standard cardiac investigations were normal (n = 8; 3 males, age 47 ± 6 years); and AL amyloid patients (n = 79; 55 males, age 62 ± 10 years). These were compared with 52 healthy volunteers and 46 patients with hypertrophic cardiomyopathy (HCM). All underwent T1 mapping (shortened modified look-locker inversion recovery); ATTR patients and mutation carriers also underwent cardiac 3,3-diphosphono-1,2- propanodicarboxylicacid (DPD) scintigraphy. Results T1 was elevated in ATTR patients compared with HCM and normal subjects (1,097 ± 43 ms vs. 1,026 ± 64 ms vs. 967 ± 34 ms, respectively; both p < 0.0001). In established cardiac ATTR amyloidosis, T1 elevation was not as high as in AL amyloidosis (AL 1,130 ± 68 ms; p = 0.01). Diagnostic performance was similar for AL and ATTR amyloid (vs. HCM: AL area under the curve 0.84 [95% confidence interval: 0.76 to 0.92]; ATTR area under the curve 0.85 [95% confidence interval: 0.77 to 0.92]; p < 0.0001). T1 tracked cardiac amyloid burden as determined semiquantitatively by DPD scintigraphy (p < 0.0001). T1 was not elevated in mutation carriers (952 ± 35 ms) but was in isolated DPD grade 1 (n = 9, 1,037 ± 60 ms; p = 0.001). Conclusions Native myocardial T1 mapping detects cardiac ATTR amyloid with similar diagnostic performance and disease tracking to AL amyloid, but with lower maximal T1 elevation, and appears to be an early disease marker. |
| spellingShingle | Fontana, M Banypersad, S Treibel, T Maestrini, V Sado, D White, S Pica, S Castelletti, S Piechnik, S Robson, M Gilbertson, J Rowczenio, D Hutt, D Lachmann, H Wechalekar, A Whelan, C Gillmore, J Hawkins, P Moon, J Native T1 mapping in transthyretin amyloidosis |
| title | Native T1 mapping in transthyretin amyloidosis |
| title_full | Native T1 mapping in transthyretin amyloidosis |
| title_fullStr | Native T1 mapping in transthyretin amyloidosis |
| title_full_unstemmed | Native T1 mapping in transthyretin amyloidosis |
| title_short | Native T1 mapping in transthyretin amyloidosis |
| title_sort | native t1 mapping in transthyretin amyloidosis |
| work_keys_str_mv | AT fontanam nativet1mappingintransthyretinamyloidosis AT banypersads nativet1mappingintransthyretinamyloidosis AT treibelt nativet1mappingintransthyretinamyloidosis AT maestriniv nativet1mappingintransthyretinamyloidosis AT sadod nativet1mappingintransthyretinamyloidosis AT whites nativet1mappingintransthyretinamyloidosis AT picas nativet1mappingintransthyretinamyloidosis AT castellettis nativet1mappingintransthyretinamyloidosis AT piechniks nativet1mappingintransthyretinamyloidosis AT robsonm nativet1mappingintransthyretinamyloidosis AT gilbertsonj nativet1mappingintransthyretinamyloidosis AT rowczeniod nativet1mappingintransthyretinamyloidosis AT huttd nativet1mappingintransthyretinamyloidosis AT lachmannh nativet1mappingintransthyretinamyloidosis AT wechalekara nativet1mappingintransthyretinamyloidosis AT whelanc nativet1mappingintransthyretinamyloidosis AT gillmorej nativet1mappingintransthyretinamyloidosis AT hawkinsp nativet1mappingintransthyretinamyloidosis AT moonj nativet1mappingintransthyretinamyloidosis |